Biofortuna

Over 25 years experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions. Previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation. More recently Simon [...]

Prior to joining Biofortuna Harry was a Consultant offering business analysis services to the Pharmaceutical and Life Science sectors. Before this he was Director of Operations at London Genetics, a company providing pharmacogenomic research projects to the pharma and biotech industry. At DxS, a personalized medicine company, he was a Genotyping Project Manager and was [...]

Geoff joins Biofortuna as Financial Director; Geoff is an experienced finance professional who has worked with various small, medium and large businesses including Altrix, Concateno, Paver Downes, Enterprise Care Group, Gemini Holdings and Novolytics. Email: geoff.orme [Email address: geoff.orme #AT# biofortuna.com - replace #AT# with @ ]

David Whitcombe is an experienced biotech director who brings a wealth of experience in successfully developing quality diagnostics and in growing biotechnology companies. David was previously part of the successful founding team of DXS, a North West UK based Molecular Diagnostics company which sold to Qiagen in 2009 in a deal worth £80M.

Mark is a serial entrepreneur with a wealth of experience of start-up and early stage businesses and is a director of a number of health and life-science companies, whose technologies range from drug development (anti-cancer) through to medical device development (implantable insulin delivery device).

Before co-founding Biofortuna Ltd, David had 7 years R&D experience in developing complex genotyping solutions within Dynal / Invitrogen Transplant Diagnostics division. David specialised in developing and project managing key projects in macro and microarray technologies. He has a BSc in Genetics from the University of Liverpool. Email: david.charvill [Email address: david.charvill #AT# biofortuna.com - [...]

Prior to setting up Biofortuna Ltd, Ben worked for Dynal / Invitrogen Transplant Diagnostics division (previously Dynal Biotech UK) where he was instrumental in developing and maintaining HLA genotyping solutions such as sequence-specific amplification (SSP) and sequence-specific oligonucelotides (SSO) as well as developing novel microarray technology . He has a BSc in Genetics from the [...]

Mike is a transplant immunologist with nearly 21 years clinical experience at Oxford and 8 years of industrial experience at Dynal / Invitrogen UK . During this time Mike has consistently developed cutting-edge genotyping and phenotyping solutions for transplant health care scientists. Mike holds a PhD in immunology from Oxford Brookes University, three patents within [...]